This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Helicos Soars on Genome Mapping Hopes

CAMBRIDGE, Mass. ( TheStreet) -- Shares of Helicos BioSciences (HLCS) leapt more than 60% Tuesday in frantic trading after a Stanford University scientist published a paper detailing how he mapped his entire personal genome within several weeks using one of Helicos's DNA sequencing machines.

The scientist, a bioengineering professor named Stephen Quake, helped found Helicos in 2003. He now sits on the company's advisory board.

Quake's paper, published Monday in the Internet edition of the journal Nature Biotechnology, details how Quake was able to complete the mapping for about $50,000, though that figure excludes the roughly $1 million price tag of the Helicos machine itself.

The paper served as a nice piece of marketing. On Tuesday, Quake's research emboldened investors, since it would seem to indicate that relatively inexpensive DNA sequencing may become a reality sooner than later, giving hope that Helicos will reap the commercial rewards with its machine.

The stock was trading midday Tuesday at $1.20, up 48 cents, or 67%, on volume of 8.3 million shares, more than 100 times the daily average turnover.

DNA sequencing is seen as away to customize disease prevention, diagnosis and treatment for a patient's individual gene codes.

Helicos, based in Cambridge, has plenty of competitors, most of them privately held. Some rival executives have questioned whether the Helicos machine and its approach to sequencing is yet accurate enough for true commercial application.

-- Written by Scott Eden from New York
Copyright 2009 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AAPL $122.77 0.00%
FB $94.20 0.03%
GOOG $627.26 0.00%
TSLA $253.39 0.15%
YHOO $37.84 0.00%

Markets

Chart of I:DJI
DOW 17,440.59 -127.94 -0.73%
S&P 500 2,067.64 -12.01 -0.58%
NASDAQ 5,039.7760 -48.8540 -0.96%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs